http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 16:30:27 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending orphan drug designation for imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <p>According to the company's press release, this is the first time the EMA has granted orphan drug designation for a treatment targeting GPP in the European Union. GPP is a chronic inflammatory skin disease characterized by widespread pustular eruptions and systemic inflammation, driven by dysregulation in the interleukin-36 signaling pathway.</p> <p>The EMA grants orphan drug designation to medicines intended for rare conditions affecting http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html Thu, 16 Jul 2026 16:30:27 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending orphan drug designation for imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <p>According to the company's press release, this is the first time the EMA has granted orphan drug designation for a treatment targeting GPP in the European Union. GPP is a chronic inflammatory skin disease characterized by widespread pustular eruptions and systemic inflammation, driven by dysregulation in the interleukin-36 signaling pathway.</p> <p>The EMA grants orphan drug designation to medicines intended for rare conditions affecting http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html Thu, 16 Jul 2026 16:30:27 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending orphan drug designation for imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <p>According to the company's press release, this is the first time the EMA has granted orphan drug designation for a treatment targeting GPP in the European Union. GPP is a chronic inflammatory skin disease characterized by widespread pustular eruptions and systemic inflammation, driven by dysregulation in the interleukin-36 signaling pathway.</p> <p>The EMA grants orphan drug designation to medicines intended for rare conditions affecting http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html Thu, 16 Jul 2026 16:30:27 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending orphan drug designation for imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <p>According to the company's press release, this is the first time the EMA has granted orphan drug designation for a treatment targeting GPP in the European Union. GPP is a chronic inflammatory skin disease characterized by widespread pustular eruptions and systemic inflammation, driven by dysregulation in the interleukin-36 signaling pathway.</p> <p>The EMA grants orphan drug designation to medicines intended for rare conditions affecting http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html Thu, 16 Jul 2026 16:30:27 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending orphan drug designation for imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <p>According to the company's press release, this is the first time the EMA has granted orphan drug designation for a treatment targeting GPP in the European Union. GPP is a chronic inflammatory skin disease characterized by widespread pustular eruptions and systemic inflammation, driven by dysregulation in the interleukin-36 signaling pathway.</p> <p>The EMA grants orphan drug designation to medicines intended for rare conditions affecting http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html Thu, 16 Jul 2026 16:30:27 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending orphan drug designation for imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <p>According to the company's press release, this is the first time the EMA has granted orphan drug designation for a treatment targeting GPP in the European Union. GPP is a chronic inflammatory skin disease characterized by widespread pustular eruptions and systemic inflammation, driven by dysregulation in the interleukin-36 signaling pathway.</p> <p>The EMA grants orphan drug designation to medicines intended for rare conditions affecting http://www.streetinsider.com/FDA/EMA+backs+orphan+drug+status+for+Vanda%27s+imsidolimab+in+rare+skin+disease/26780049.html Thu, 16 Jul 2026 16:30:27 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency</span> (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+EMA+Positive+Opinion+for+Orphan+Drug+Designation+of+Imsidolimab+for+Generalized+Pustular+Psoriasis+-+A+Milestone+Recognition+of+GPP+as+a+Distinct+Rare+Disease+in+Europe/26780041.html Thu, 16 Jul 2026 16:30:00 -0400 A.05963196 A.31066700 O.00840259 O.05375760 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with <span>Rahal Letterman Lanigan Racing</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1883627/Vanda-Pharmaceuticals-Inc-NEREUS.jpg?id=OA2765094" http://www.streetinsider.com/Press+Releases/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html Wed, 15 Jul 2026 16:30:00 -0400 O.00840259 VNDA http://www.streetinsider.com/Press+Releases/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with <span>Rahal Letterman Lanigan Racing</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1883627/Vanda-Pharmaceuticals-Inc-NEREUS.jpg?id=OA2765094" http://www.streetinsider.com/Press+Releases/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html Wed, 15 Jul 2026 16:30:00 -0400 O.00840259 VNDA http://www.streetinsider.com/PRNewswire/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with <span>Rahal Letterman Lanigan Racing</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1883627/Vanda-Pharmaceuticals-Inc-NEREUS.jpg?id=OA2765094" http://www.streetinsider.com/PRNewswire/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html Wed, 15 Jul 2026 16:30:00 -0400 O.00840259 VNDA http://www.streetinsider.com/PRNewswire/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with <span>Rahal Letterman Lanigan Racing</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1883627/Vanda-Pharmaceuticals-Inc-NEREUS.jpg?id=OA2765094" http://www.streetinsider.com/PRNewswire/NEREUS%E2%84%A2+Powers+Forward%3A+Sponsors+No.+47+IndyCar+Entry%2C+Celebrating+47+Years+Since+Last+New+U.S.+Motion+Sickness+Treatment/26774493.html Wed, 15 Jul 2026 16:30:00 -0400 O.00840259 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+Participation+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26757642.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location> on <chron>Thursday, July 16, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS637926/VandaLogo-v1.jpg?id=OA2759097" title="Vanda Logo" alt="Vanda Logo" http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+Participation+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26757642.html Fri, 10 Jul 2026 16:30:00 -0400 O.00840259 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+Participation+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26757642.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location> on <chron>Thursday, July 16, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS637926/VandaLogo-v1.jpg?id=OA2759097" title="Vanda Logo" alt="Vanda Logo" http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Announces+Participation+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26757642.html Fri, 10 Jul 2026 16:30:00 -0400 O.00840259 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+Participation+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26757642.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location> on <chron>Thursday, July 16, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS637926/VandaLogo-v1.jpg?id=OA2759097" title="Vanda Logo" alt="Vanda Logo" http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Announces+Participation+in+the+B.+Riley+Securities+2026+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26757642.html Fri, 10 Jul 2026 16:30:00 -0400 O.00840259 VNDA